These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
9. Long-term effects of volanesorsen on triglycerides and pancreatitis in patients with familial chylomicronaemia syndrome (FCS) in the UK Early Access to Medicines Scheme (EAMS). Jones A; Peers K; Wierzbicki AS; Ramachandran R; Mansfield M; Dawson C; Ochoa-Ferraro A; Soran H; Jenkinson F; McDowell I; Downie P; Hamilton P; Jones RD Atherosclerosis; 2023 Jun; 375():67-74. PubMed ID: 37253281 [TBL] [Abstract][Full Text] [Related]
10. 10-Year Comparative Follow-up of Familial versus Multifactorial Chylomicronemia Syndromes. Belhassen M; Van Ganse E; Nolin M; Bérard M; Bada H; Bruckert E; Krempf M; Rebours V; Valero R; Moulin P J Clin Endocrinol Metab; 2021 Mar; 106(3):e1332-e1342. PubMed ID: 33221907 [TBL] [Abstract][Full Text] [Related]
11. Efficacy and safety of lomitapide in familial chylomicronaemia syndrome. Cefalù AB; D'Erasmo L; Iannuzzo G; Noto D; Giammanco A; Montali A; Zambon A; Forte F; Suppressa P; Giannini S; Barbagallo CM; Ganci A; Nardi E; Vernuccio F; Caldarella R; Ciaccio M; Arca M; Averna M Atherosclerosis; 2022 Oct; 359():13-19. PubMed ID: 36152419 [TBL] [Abstract][Full Text] [Related]
12. Familial chylomicronemia syndrome: an under-recognized cause of severe hypertriglyceridaemia. Baass A; Paquette M; Bernard S; Hegele RA J Intern Med; 2020 Apr; 287(4):340-348. PubMed ID: 31840878 [TBL] [Abstract][Full Text] [Related]
13. Analyses of familial chylomicronemia syndrome in Pereira, Colombia 2010-2020: a cross-sectional study. Rodriguez FH; Estrada JM; Quintero HMA; Nogueira JP; Porras-Hurtado GL Lipids Health Dis; 2023 Mar; 22(1):43. PubMed ID: 36978188 [TBL] [Abstract][Full Text] [Related]
14. Familial Chylomicronemia Syndrome (FCS): Recent Data on Diagnosis and Treatment. Gallo A; Béliard S; D'Erasmo L; Bruckert E Curr Atheroscler Rep; 2020 Aug; 22(11):63. PubMed ID: 32852651 [TBL] [Abstract][Full Text] [Related]
15. Evaluation of the chylomicron-TG to VLDL-TG ratio for type I hyperlipoproteinemia diagnostic. Rioja J; Ariza MJ; García-Casares N; Coca-Prieto I; Arrobas T; Muñiz-Grijalvo O; Mangas A; Ibarretxe D; Sánchez-Chaparro MÁ; Valdivielso P Eur J Clin Invest; 2020 Dec; 50(12):e13345. PubMed ID: 32649781 [TBL] [Abstract][Full Text] [Related]
16. Spectrum of Mutations and Long-Term Clinical Outcomes in Genetic Chylomicronemia Syndromes. D'Erasmo L; Di Costanzo A; Cassandra F; Minicocci I; Polito L; Montali A; Ceci F; Arca M Arterioscler Thromb Vasc Biol; 2019 Dec; 39(12):2531-2541. PubMed ID: 31619059 [TBL] [Abstract][Full Text] [Related]
17. Clinical characterization and mutation spectrum of patients with hypertriglyceridemia in a German outpatient clinic. Bardey F; Rieck L; Spira D; März W; Binner P; Schwab S; Kleber ME; Danyel M; Barkowski R; Bobbert T; Spranger J; Steinhagen-Thiessen E; Demuth I; Kassner U J Lipid Res; 2024 Jul; ():100589. PubMed ID: 38969064 [TBL] [Abstract][Full Text] [Related]
18. Non-Alcoholic Fatty Liver in Patients with Chylomicronemia. Maltais M; Brisson D; Gaudet D J Clin Med; 2021 Feb; 10(4):. PubMed ID: 33572376 [TBL] [Abstract][Full Text] [Related]